- Category: HCV Treatment
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
The advent of direct-acting antiviral agents targeting hepatitis C virus (HCV) have brought about a new era of treatment, but many questions remain about how these new medications will be used in real-world clinical practice.
In a panel discussion following the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta, Cami Graham from Beth Israel Deaconess Medical Center, Kenneth Sherman from the University of Cincinnati, and Kristen Marks from Weill Cornell Medical Center spoke with Liz Highleyman of HIVandHepatitis.com about implications of new therapies for hepatitis C patients and providers.
[Hepatitis C panel discussion, CROI 2013, Atlanta, March 6, 2013]